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Résumé en
anglais
OPA1 is a GTPase that controls several functions, such as mitochondrial dynamics and
energetics, mtDNA maintenance and cristae integrity. In the last years, there have
been described other cellular pathways and mechanisms involving OPA1 directly or
through its interaction. All this new information, by implementing our knowledge on
OPA1 is instrumental to elucidating the pathogenic mechanisms of OPA1 mutations.
Indeed, these are associated with dominant optic atrophy (DOA), one of the most
common inherited optic neuropathies, and with an increasing number of
heterogeneous neurodegenerative disorders. In this review, we overview all recent
findings on OPA1 protein functions, on its dysfunction and related clinical phenotypes,
focusing on the current therapeutic options and future perspectives to treat DOA and
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